|BioMed Bytes: MedaSorb Technologies (OTC:MSBT) , BioDelivery Sciences (NASDAQ:BDSI)|
|By Vinny Cassano|
|Thursday, 22 October 2009 05:48|
Shares of MedaSorb Technologies Corporation (OTC:MSBT) continued to run on Wednesday, closing at forty three cents, another thirty four percent to the upside. Wednesday's close makes the stock a near triple over the past five trading days and a seven-bagger over the past few months.
It's hard not to imagine a pullback after a run like that, but with a market cap of still under twenty million, I think that there is still more room for an additional speculative move to the upside based on the potential of the company's treatment for sever sepsis, Cytosorb, which is nearing the conclusion of a European trial.
A run to a dollar is plausible, in my opinion, as it gets closer to trial-results time, but I also suggest that investors who are holding from under ten take a little bit of profit on the way up; as what happened to AGEN re-iterated on Wednesday, nothing is a sure thing in the stock market.
Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded down by nearly seven percent on Wednesday to close the day at $4.53 - a price that I still consider a good one to buy for those with a long term outlook.
Disclosure: Long MSBT, BDSI